carmustine has been researched along with Astrocytoma in 138 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Astrocytoma: Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 9.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 9.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 9.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 9.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma." | 9.11 | Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. ( Buckner, JC; Dinapoli, RP; Fitch, TR; Krishnan, S; Maurer, MJ; Nordstrom, K; O'Fallon, JR; Rao, RD; Scheithauer, B; Schomberg, PJ, 2005) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 9.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 9.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 7.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 7.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "To determine any differences in outcome for patients with anaplastic astrocytoma (AA) treated with adjuvant carmustine (BCNU) versus procarbazine, lomustine, and vincristine (PCV) chemotherapy." | 7.70 | Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. ( Curran, WJ; Kramer, S; Leibel, S; Nelson, DF; Prados, MD; Scott, C, 1999) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 7.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "Fourteen glioblastoma patients and 10 anaplastic astrocytoma patients were treated." | 6.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 6.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 5.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| "Adding temozolomide (TMZ) to radiation for patients with newly-diagnosed anaplastic astrocytomas (AAs) is common clinical practice despite the lack of prospective studies demonstrating a survival advantage." | 5.22 | The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. ( Abuali, I; Grossman, SA; Lu, Y; Strowd, RE; Ye, X, 2016) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 5.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 5.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma." | 5.11 | Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors. ( Atkins, J; Bahary, JP; Barger, G; Buckner, J; Bushunow, P; Cairncross, G; Chang, SM; Choucair, A; Curran, W; Dolinskas, C; Gilbert, M; Kresl, J; Louis, DN; Mehta, M; Seiferheld, W; Share, R; Thoron, L, 2004) |
| "To evaluate the efficacy of preradiotherapy (RT) chemotherapy with carmustine, cisplatin, and oral etoposide combined with RT in the treatment of newly diagnosed anaplastic astrocytoma." | 5.11 | Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. ( Buckner, JC; Dinapoli, RP; Fitch, TR; Krishnan, S; Maurer, MJ; Nordstrom, K; O'Fallon, JR; Rao, RD; Scheithauer, B; Schomberg, PJ, 2005) |
| "To investigate the safety of thrice-daily hyperfractionated radiotherapy (RT) given in conjunction with BCNU (carmustine) in high-grade gliomas." | 5.10 | Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. ( Buckner, JC; Dinapoli, RP; Earle, JD; O'Fallon, J; Rao, RD; Thomé, SD, 2002) |
| "To evaluate the activity and toxicity of carmustine (BCNU) and cisplatin administered as a 72-hour continuous intravenous infusion before radiation in adults with newly diagnosed high-grade astrocytomas." | 5.08 | Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. ( Grossman, SA; Kleinberg, L; Piantadosi, S; Sheidler, V; Wharam, M; Yue, N; Zeltzman, M, 1997) |
| "Seventy-five patients harboring astrocytomas received 4 cycles of infra-ophthalmic carotid injections of BCNU, combined with vincristine intravenously and procarbazine orally." | 5.07 | Combined intra-arterial chemotherapy followed by radiation in astrocytomas. ( Hager, B; Hannisdal, E; Heier, M; Hirschberg, H; Nome, O; Watne, K; Wester, K, 1992) |
| "Seventy-nine patients with malignant gliomas (19 anaplastic astrocytomas and 60 glioblastoma multiforme) received 4 cycles of infra-ophthalmic carotid injection of 160 mg carmustine, 2 mg vincristine IV and procarbazine orally 50 mg 3 times daily for 1 week, followed by whole-brain irradiation, with a midpoint dose of 54 Gy/6 weeks." | 5.07 | Combined intra-arterial chemotherapy and irradiation of malignant gliomas. ( Hager, B; Hirschberg, H; Nome, O; Watne, K, 1991) |
| "Between April 1986 and March 1989, ten patients under 21 years of age with histologically confirmed malignant astrocytoma, received marrow-ablative chemotherapy with either thiotepa and Etoposide (five patients) or thiotepa, Etoposide and BCNU (five patients), followed by bone marrow 'rescue'." | 5.06 | High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence. ( August, C; Bayever, E; Finlay, JL; Freid, A; Kamani, N; Kramer, E; Packer, R; Rorke, L; Sutton, L; Zimmerman, R, 1990) |
| "In Brain Tumor Cooperative Group Study 77-02, eleven institutions randomized 603 adult patients with supratentorial malignant glioma to one of four treatment groups following surgery: conventional radiotherapy (6000 cGy in 30-35 fractions) + BCNU, conventional radiotherapy + streptozotocin, hyperfractionated (twice daily) radiotherapy (6600 cGy in 60 fractions) + BCNU, and conventional radiotherapy with misonidazole followed by BCNU." | 5.06 | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. ( Burger, PC; Deutsch, M; Green, SB; Mealey, J; Paoletti, P; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA, 1989) |
| "Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)." | 3.74 | Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008) |
| "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival." | 3.74 | Fatal outcome related to carmustine implants in glioblastoma multiforme. ( Barcia, JA; Barcia-Mariño, C; Gallego, JM, 2007) |
| "We have reported that carmustine (BCNU) and cisplatin administered before, during, and after radiotherapy did not improve the survival of patients with high-grade astrocytomas and were associated with more serious toxicities than radiotherapy plus BCNU." | 3.73 | Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma. ( Jung, SM; Liau, CT; Tseng, CK; Wei, KC, 2005) |
| "p53 inactivation sensitizes U87MG astrocytic glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and temozolomide (TMZ), drugs used clinically to treat high-grade astrocytomas." | 3.73 | Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. ( Cairncross, JG; Mymryk, JS; Xu, GW, 2005) |
| "The effects of a combination of simvastatin, a cholesterol-lowering agent, and carmustine (BCNU; N,N'-bis(2-chloroethyl)-N-nitrosourea) on experimental C6 glioma were studied in vitro and in vivo." | 3.69 | In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin. ( Baetta, R; Butti, G; Davegna, C; De Renzis, MR; Fumagalli, R; Magrassi, L; Mazzini, G; Paoletti, R; Pezzotta, S; Soma, MR, 1995) |
| "We describe eight patients who developed interstitial pulmonary fibrosis following BCNU (carmustine) therapy for cerebral tumours." | 3.68 | Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. ( Gattamaneini, HR; Hasleton, PS; Kalra, SJ; Lynch, P; O'Driscoll, BR; Poulter, LW; Webster, A; Woodcock, AA, 1991) |
| "The authors have used phosphorus magnetic resonance spectroscopy to monitor pH changes in malignant gliomas following treatment with intravenous and intra-arterial 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU)." | 3.67 | Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy. ( Arnold, DL; Emrich, J; Feindel, W; Shoubridge, EA; Villemure, JG, 1989) |
| "Intensive monochemotherapy with carmustine (BCNU) (either 1,050, 1,200, or 1,350 mg/m2) and cryopreserved autologous marrow transplantation was administered to 36 patients with malignant glioma: 27 with progressive disease and nine without progression (adjuvant therapy group)." | 3.67 | Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. ( Fay, JW; Herzig, GP; Herzig, RH; Lazarus, HM; Phillips, GL; Schold, C; Wolff, SN, 1986) |
| "Comparative studies were carried out to evaluate the cytotoxic effectiveness of the nitrosureas ACNU (Nimustine) and BCNU (Carmustine) at equitoxic dose levels in xenografts from two astrocytomas grades III/IV (Li, Re) and one oligodendroglioma grade III (Oe) on nude mice." | 3.67 | Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas. ( Bamberg, M; Budach, V; Gerhard, L; Stuschke, M, 1988) |
| "Fourteen glioblastoma patients and 10 anaplastic astrocytoma patients were treated." | 2.71 | Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy. ( Abrey, LE; Kleber, M; Malkin, MG; Raizer, JJ, 2004) |
| " Three patients were treated at each dosing level (AUC=2-6), and 4 patients were treated at an AUC=5." | 2.71 | A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme. ( Asher, A; Fraser, R; Heafner, M; Kim, JW; Limentani, SA, 2005) |
| " The recommended dosage for TEMO for a phase II study of this combination is 200 mg/m2 per day for 5 days." | 2.70 | Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. ( Affronti, ML; Cokgor, L; Early, M; Edwards, S; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; McLendon, RE; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, JH; Stafford-Fox, V; Tourt-Uhlig, S; Zaknoen, S, 2001) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | 2.69 | Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| "Histology included anaplastic astrocytoma (AA) in 15 patients and glioblastoma multiforme (GBM) in 49 patients." | 2.68 | Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study. ( Antunovic, V; Djuric, L; Grujicic, D; Jeremic, B; Shibamoto, Y, 1995) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Patients with anaplastic astrocytoma, or glioblastoma multiforme, age 18-70 years with a Karnofsky performance status of 40-100 were stratified according to age, Karnofsky performance status, and histology, and were randomized." | 2.67 | Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. ( Ahmad, K; Constine, LS; Curran, WJ; Mohiuddin, M; Murray, K; Nelson, DF; Nelson, JS; Powlis, WD; Scott, C; Weinstein, AS, 1993) |
| "Patients with anaplastic astrocytoma had a median survival of 27 months as compared to 8 months for patients with glioblastoma." | 2.65 | Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. ( Chang, CH; Horton, J; Kramer, S; Nelson, JS; Perez-Tamayo, R; Salazer, O; Schoenfeld, D; Tsukada, Y; Weinstein, A, 1983) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Carmustine (BCNU) has been shown to have limited activity at conventional dosage but is still the standard chemotherapy." | 2.41 | [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma]. ( Alcaraz, L; Benboubker, L; Bergemer-Fouquet, AM; Calais, G; Colombat, P; Destrieux, C; Jan, M; Linassier, C, 2001) |
| "Metastatic brain tumors are frequently treated by radiation therapy alone." | 2.40 | [Chemoradiation for malignant brain tumors]. ( Matsutani, M, 1997) |
| "14 other patients with astrocytic glioma, two of whom are children, are reported in the literature to have diffuse bone marrow metastasis." | 2.40 | Bone marrow metastasis in astrocytic gliomata. ( Grimard, L; Hsu, E; Jimenez, C; Keene, D; Matzinger, MA; Ventureyra, E; Wang, HS, 1998) |
| "Valproic acid (VPA) has been recently investigated for its anticancer properties in different tumors, including malignant gliomas." | 1.34 | Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines. ( Balzarotti, M; Boiardi, A; Calatozzolo, C; Ciusani, E; Croci, D; de Grazia, U; Salmaggi, A, 2007) |
| "Histology included anaplastic astrocytoma (60) (AA), and glioblastoma multiforme (312) (GBM)." | 1.34 | Imaging response in malignant glioma, RTOG 90-06. ( Berkey, B; Curran, WJ; Fishbach, J; Jones, CU; Lustig, RA; Movsas, B; Scarantino, C; Seiferheld, W; Simpson, JR; Yung, AW, 2007) |
| "With respect to the cerebral edema that can be associated with the carmustine implants, there can appear images in follow-up that are suggestive of relapse." | 1.33 | Patient with resected anaplastic astrocytoma and an image suggestive of relapse. ( Carrato Mena, A; Guillén Ponce, C; Maciá Escalante, S; Rodríguez Lescure, A; Sáez Castán, J; Segura Ibáñez, JM, 2006) |
| "Out of 26 patients with anaplastic astrocytomas 11 were originally low-grade where no postoperative radiotherapy was applied." | 1.31 | BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas. ( Afra, D; Sipos, L; Vitanovics, D, 2002) |
| "Seven of ten anaplastic astrocytomas were composed primarily of 2n+/- cells and were BCNU resistant." | 1.29 | Chromosome number and carmustine sensitivity in human gliomas. ( Ebrahim, SA; Galicich, JH; Mohamed, AN; Pu, PY; Shapiro, JR; Shapiro, WR, 1993) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| " A method to individualize IA drug dosage is needed to provide each patient with the safest, most effective dose." | 1.28 | Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation. ( Bobo, H; Kapp, JP; Vance, R, 1992) |
| "The occurrence of pulmonary disease associated with long-term BCNU therapy is reported in two patients treated for astrocytoma grade II whose clinical presentations of pulmonary complications and corresponding tissue alterations showed striking differences." | 1.27 | BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes. ( Banerji, B; Greenwald, ES; Koss, LG; Mitsudo, SM, 1984) |
| "Four who had nonirradiated anaplastic astrocytomas all responded and survived for 38+ to 48." | 1.27 | Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study. ( Avellanosa, AM; Barua, NR; Hong, CI; Patel, A; West, CR, 1983) |
| "Diaziquone (AZQ) is a lypophilic alkylating agent that crosses the blood-brain barrier and has shown broad activity in animal tumor models." | 1.27 | Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas. ( Bender, JF; Chaffee, B; Ensminger, WD; Gebarski, S; Greenberg, HS; Grillo-Lopez, AJ; Layton, PB; Meyer, M, 1986) |
| " Sorted populations of cells from 5 tumors had dose-response curves that were similar, although differences in cell kill of up to a half-log were commonly found between cells from different DNA peaks treated with the same BCNU dose." | 1.27 | Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content. ( Dougherty, DV; Hoshino, T; Kobayashi, S; Rosenblum, ML, 1984) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| "A dose-response relationship for the dependence of the cytotoxic activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) on extracellular pH has been established." | 1.27 | pH-induced modification of BCNU toxicity on glial cells. ( Röttinger, EM; Smith, BD; Weidenmaier, W, 1986) |
| "Six children with grade II astrocytomas were treated with combination chemotherapy consisting of 1,3 bis(2-chloroethyl) 1-nitrosourea (BCNU)." | 1.26 | Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children. ( Bremer, AM; Cohen, M; Freeman, AI; Sinks, LF; Sumer, T; Thomas, PR, 1978) |
| " The BCNU dose-response curve was exponential up to a dose of 0." | 1.25 | In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea. ( Barker, M; Knebel, KD; Rosenblum, ML; Wheeler, KT; Wilson, CB, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 66 (47.83) | 18.7374 |
| 1990's | 31 (22.46) | 18.2507 |
| 2000's | 32 (23.19) | 29.6817 |
| 2010's | 9 (6.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faccion, RS | 1 |
| Bernardo, PS | 1 |
| de Lopes, GPF | 1 |
| Bastos, LS | 1 |
| Teixeira, CL | 1 |
| de Oliveira, JA | 1 |
| Fernandes, PV | 1 |
| Dubois, LG | 1 |
| Chimelli, L | 1 |
| Maia, RC | 1 |
| Strowd, RE | 1 |
| Abuali, I | 1 |
| Ye, X | 1 |
| Lu, Y | 1 |
| Grossman, SA | 2 |
| Finlay, JL | 2 |
| Dhall, G | 1 |
| Boyett, JM | 1 |
| Dunkel, IJ | 1 |
| Gardner, SL | 1 |
| Goldman, S | 1 |
| Yates, AJ | 1 |
| Rosenblum, MK | 1 |
| Stanley, P | 1 |
| Zimmerman, RA | 1 |
| Wallace, D | 1 |
| Pollack, IF | 1 |
| Packer, RJ | 1 |
| McGirt, MJ | 3 |
| Chaichana, KL | 1 |
| Gathinji, M | 1 |
| Attenello, FJ | 1 |
| Than, K | 1 |
| Olivi, A | 1 |
| Weingart, JD | 1 |
| Brem, H | 2 |
| Quiñones-Hinojosa, AR | 1 |
| Rusthoven, KE | 1 |
| Olsen, C | 1 |
| Franklin, W | 1 |
| Kleinschmidt-DeMasters, BK | 2 |
| Kavanagh, BD | 1 |
| Gaspar, LE | 2 |
| Lillehei, K | 1 |
| Waziri, A | 1 |
| Damek, DM | 1 |
| Chen, C | 1 |
| Bock, HC | 1 |
| Cohnen, J | 1 |
| Keric, N | 1 |
| Kantelhardt, SR | 1 |
| Giese, A | 1 |
| Noël, G | 1 |
| Schott, R | 1 |
| Froelich, S | 1 |
| Gaub, MP | 1 |
| Boyer, P | 1 |
| Fischer-Lokou, D | 1 |
| Dufour, P | 1 |
| Kehrli, P | 1 |
| Maitrot, D | 1 |
| Dixit, S | 1 |
| Hingorani, M | 1 |
| Achawal, S | 1 |
| Scott, I | 1 |
| Márquez-Rivas, J | 1 |
| Rivero-Garvía, M | 1 |
| Mayorga-Buiza, MJ | 1 |
| Pizer, B | 1 |
| Salehzadeh, A | 1 |
| Brodbelt, A | 1 |
| Mallucci, C | 1 |
| Afra, D | 3 |
| Sipos, L | 2 |
| Vitanovics, D | 2 |
| Cutts, J | 1 |
| Lee, G | 1 |
| Berarducci, M | 1 |
| Thomas, C | 1 |
| Dempsey, PK | 1 |
| Kadish, SP | 1 |
| Durando, X | 1 |
| Lemaire, JJ | 1 |
| Tortochaux, J | 1 |
| Van-Praagh, I | 1 |
| Kwiatkowski, F | 1 |
| Vincent, C | 1 |
| Bailly, C | 1 |
| Verrelle, P | 1 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Bay, JO | 1 |
| Reardon, DA | 2 |
| Quinn, JA | 4 |
| Rich, JN | 4 |
| Gururangan, S | 3 |
| Vredenburgh, J | 2 |
| Sampson, JH | 3 |
| Provenzale, JM | 4 |
| Walker, A | 2 |
| Badruddoja, M | 1 |
| Tourt-Uhlig, S | 4 |
| Herndon, JE | 4 |
| Dowell, JM | 1 |
| Affronti, ML | 3 |
| Jackson, S | 2 |
| Allen, D | 2 |
| Ziegler, K | 2 |
| Silverman, S | 1 |
| Bohlin, C | 2 |
| Friedman, AH | 5 |
| Bigner, DD | 4 |
| Friedman, HS | 6 |
| Schweitzer, H | 1 |
| Lentz, C | 1 |
| Chang, SM | 1 |
| Seiferheld, W | 2 |
| Curran, W | 1 |
| Share, R | 1 |
| Atkins, J | 1 |
| Choucair, A | 1 |
| Kresl, J | 1 |
| Thoron, L | 1 |
| Cairncross, G | 2 |
| Gilbert, M | 1 |
| Bahary, JP | 1 |
| Dolinskas, C | 1 |
| Louis, DN | 1 |
| Bushunow, P | 1 |
| Buckner, J | 1 |
| Barger, G | 1 |
| Mehta, M | 1 |
| Raizer, JJ | 1 |
| Malkin, MG | 2 |
| Kleber, M | 1 |
| Abrey, LE | 1 |
| Rao, RD | 2 |
| Krishnan, S | 1 |
| Fitch, TR | 1 |
| Schomberg, PJ | 1 |
| Dinapoli, RP | 4 |
| Nordstrom, K | 1 |
| Scheithauer, B | 1 |
| O'Fallon, JR | 1 |
| Maurer, MJ | 1 |
| Buckner, JC | 2 |
| Liau, CT | 1 |
| Wei, KC | 1 |
| Tseng, CK | 1 |
| Jung, SM | 1 |
| Limentani, SA | 1 |
| Asher, A | 1 |
| Heafner, M | 1 |
| Kim, JW | 1 |
| Fraser, R | 1 |
| Fadeev, BP | 1 |
| Zhabina, RM | 1 |
| Webster, M | 1 |
| Gertler, S | 1 |
| Perry, J | 1 |
| Wainman, N | 1 |
| Eisenhauer, E | 1 |
| Xu, GW | 1 |
| Mymryk, JS | 1 |
| Cairncross, JG | 3 |
| Nicolardi, L | 1 |
| DeAngelis, LM | 1 |
| Maciá Escalante, S | 1 |
| Rodríguez Lescure, A | 1 |
| Segura Ibáñez, JM | 1 |
| Sáez Castán, J | 1 |
| Guillén Ponce, C | 1 |
| Carrato Mena, A | 1 |
| Lustig, RA | 1 |
| Berkey, B | 1 |
| Yung, AW | 1 |
| Scarantino, C | 1 |
| Movsas, B | 1 |
| Jones, CU | 1 |
| Simpson, JR | 1 |
| Fishbach, J | 1 |
| Curran, WJ | 5 |
| Gallego, JM | 1 |
| Barcia, JA | 1 |
| Barcia-Mariño, C | 1 |
| Ciusani, E | 1 |
| Balzarotti, M | 1 |
| Calatozzolo, C | 1 |
| de Grazia, U | 1 |
| Boiardi, A | 4 |
| Salmaggi, A | 3 |
| Croci, D | 1 |
| Hildebrand, J | 1 |
| Gorlia, T | 1 |
| Kros, JM | 1 |
| Frenay, M | 1 |
| Omuro, A | 1 |
| Stupp, R | 1 |
| Lacombe, D | 1 |
| Allgeier, A | 1 |
| van den Bent, MJ | 1 |
| Wolff, JE | 1 |
| Berrak, S | 1 |
| Koontz Webb, SE | 1 |
| Zhang, M | 1 |
| Kobiakov, GL | 1 |
| Kobayashi, S | 1 |
| Hoshino, T | 1 |
| Dougherty, DV | 2 |
| Rosenblum, ML | 3 |
| Stewart, DJ | 1 |
| Benoit, B | 1 |
| Richard, MT | 1 |
| Hugenholtz, H | 1 |
| Dennery, J | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Grahovac, Z | 1 |
| Belanger, G | 1 |
| Maroun, JA | 1 |
| Gerosa, M | 1 |
| Reese, C | 1 |
| Barger, GR | 1 |
| Davis, RL | 1 |
| Levin, VA | 5 |
| Wilson, CB | 8 |
| Kelly, KA | 1 |
| Kirkwood, JM | 1 |
| Kapp, DS | 1 |
| Grimson, BS | 1 |
| Mahaley, MS | 3 |
| Dubey, HD | 1 |
| Dudka, L | 1 |
| Greenberg, HS | 3 |
| Dara, P | 1 |
| Slater, LM | 1 |
| Talreja, D | 1 |
| Armentrout, SA | 1 |
| West, CR | 1 |
| Avellanosa, AM | 1 |
| Barua, NR | 1 |
| Patel, A | 1 |
| Hong, CI | 1 |
| Kapp, JP | 3 |
| Vance, R | 2 |
| Chang, CH | 3 |
| Horton, J | 2 |
| Schoenfeld, D | 1 |
| Salazer, O | 1 |
| Perez-Tamayo, R | 1 |
| Kramer, S | 2 |
| Weinstein, A | 1 |
| Nelson, JS | 5 |
| Tsukada, Y | 1 |
| Butti, G | 2 |
| Knerich, R | 2 |
| Tanghetti, B | 1 |
| Adinolfi, D | 1 |
| Gaetani, P | 1 |
| Buoncristiani, P | 1 |
| Paoletti, P | 5 |
| Bradley, NJ | 1 |
| Darling, JL | 2 |
| Oktar, N | 1 |
| Bloom, HJ | 2 |
| Thomas, DG | 2 |
| Davies, AJ | 1 |
| Eagan, RT | 2 |
| Hermann, RC | 2 |
| Groover, RV | 2 |
| Layton, DD | 2 |
| Layton, PB | 3 |
| Stetson, PL | 1 |
| Ensminger, WD | 2 |
| Gyves, JW | 1 |
| Trovó, MG | 1 |
| De Paoli, A | 1 |
| Franchin, G | 1 |
| Roncadin, M | 1 |
| Veronesi, A | 1 |
| Tirelli, U | 1 |
| Galligioni, E | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Mitsudo, SM | 1 |
| Greenwald, ES | 1 |
| Banerji, B | 1 |
| Koss, LG | 1 |
| Shapiro, WR | 4 |
| Siddiqi, TS | 1 |
| Buchheit, WA | 1 |
| Wilson, KS | 1 |
| Brigden, ML | 1 |
| Alexander, S | 1 |
| Worth, A | 1 |
| Scott, M | 1 |
| Klein, RC | 1 |
| Paddison, RM | 1 |
| Patten, GA | 1 |
| Billi, JE | 1 |
| Rotman, HH | 1 |
| Jeremic, B | 1 |
| Grujicic, D | 1 |
| Antunovic, V | 1 |
| Djuric, L | 1 |
| Shibamoto, Y | 1 |
| Soma, MR | 1 |
| Baetta, R | 1 |
| De Renzis, MR | 1 |
| Mazzini, G | 1 |
| Davegna, C | 1 |
| Magrassi, L | 1 |
| Pezzotta, S | 3 |
| Paoletti, R | 1 |
| Fumagalli, R | 3 |
| Nelson, DF | 5 |
| Scott, C | 2 |
| Weinstein, AS | 2 |
| Ahmad, K | 1 |
| Constine, LS | 1 |
| Murray, K | 1 |
| Powlis, WD | 1 |
| Mohiuddin, M | 1 |
| Shapiro, JR | 2 |
| Pu, PY | 2 |
| Mohamed, AN | 2 |
| Galicich, JH | 1 |
| Ebrahim, SA | 2 |
| Halperin, EC | 1 |
| Gaspar, L | 1 |
| Imperato, J | 1 |
| Salter, M | 1 |
| Herndon, J | 1 |
| Dowling, S | 1 |
| Wedge, SR | 1 |
| Newlands, ES | 1 |
| Scott, CB | 2 |
| Farnan, NC | 1 |
| Murray, KJ | 1 |
| Fischbach, AJ | 2 |
| Lee, SM | 1 |
| Reid, H | 1 |
| Elder, RH | 1 |
| Thatcher, N | 1 |
| Margison, GP | 1 |
| Lunardi, P | 1 |
| Osman Farah, J | 1 |
| Mastronardi, L | 1 |
| Puzzilli, F | 1 |
| Lo Bianco, FM | 1 |
| Hochberg, F | 1 |
| Prados, M | 2 |
| Russell, C | 1 |
| Weissman, D | 1 |
| Evans, R | 1 |
| Cook, P | 1 |
| Burton, G | 1 |
| Eisenberg, PD | 1 |
| Valenzuela, R | 1 |
| Verkh, L | 1 |
| Silvani, A | 3 |
| Pozzi, A | 1 |
| Farinotti, M | 1 |
| Fariselli, L | 1 |
| Broggi, G | 2 |
| Wharam, M | 1 |
| Sheidler, V | 1 |
| Kleinberg, L | 1 |
| Zeltzman, M | 1 |
| Yue, N | 1 |
| Piantadosi, S | 1 |
| Matsutani, M | 1 |
| Hsu, E | 1 |
| Keene, D | 1 |
| Ventureyra, E | 1 |
| Matzinger, MA | 1 |
| Jimenez, C | 1 |
| Wang, HS | 1 |
| Grimard, L | 1 |
| Prados, MD | 1 |
| Leibel, S | 1 |
| Bauman, GS | 1 |
| MacDonald, W | 1 |
| Moore, E | 1 |
| Ramsey, DA | 1 |
| Fisher, BJ | 1 |
| Amberger, VR | 1 |
| Del Maestro, RM | 1 |
| Vlassenko, AG | 1 |
| Thiessen, B | 1 |
| Beattie, BJ | 1 |
| Blasberg, RG | 1 |
| Nutt, CL | 1 |
| Noble, M | 1 |
| Chambers, AF | 1 |
| Pluda, J | 1 |
| Ewesuedo, RB | 1 |
| Long, L | 1 |
| Cokgor, I | 1 |
| Colvin, OM | 1 |
| Haglund, MM | 1 |
| Ashley, DM | 1 |
| Sampson, J | 1 |
| Pegg, AE | 1 |
| Moschel, RC | 1 |
| McLendon, RE | 2 |
| Stewart, ES | 1 |
| Garcia-Turner, AM | 1 |
| Dolan, ME | 1 |
| Eoli, M | 1 |
| Pollo, B | 1 |
| Milanesi, I | 2 |
| Cokgor, L | 1 |
| Edwards, S | 1 |
| Stafford-Fox, V | 1 |
| Zaknoen, S | 1 |
| Early, M | 1 |
| Linassier, C | 1 |
| Destrieux, C | 1 |
| Benboubker, L | 1 |
| Alcaraz, L | 1 |
| Bergemer-Fouquet, AM | 1 |
| Jan, M | 1 |
| Calais, G | 1 |
| Colombat, P | 1 |
| Villavicencio, AT | 1 |
| Bulsara, KR | 1 |
| Thomé, SD | 1 |
| O'Fallon, J | 1 |
| Earle, JD | 1 |
| Crafts, DC | 2 |
| Schultz, MJ | 1 |
| Boldrey, EB | 5 |
| Enot, KJ | 4 |
| Pischer, TL | 3 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Gutin, P | 1 |
| Drafts, D | 1 |
| Saez, RJ | 1 |
| Campbell, RJ | 1 |
| Laws, ER | 1 |
| Gentry, RE | 1 |
| Walker, MD | 1 |
| Hoffman, WF | 1 |
| Seager, ML | 1 |
| Davis, R | 1 |
| Wara, WM | 1 |
| Irwin, L | 1 |
| Baldini, M | 1 |
| Princi, L | 1 |
| Cigánek, L | 1 |
| Kalina, P | 1 |
| Silvanová, E | 1 |
| Weiss, JF | 1 |
| Sumer, T | 1 |
| Freeman, AI | 1 |
| Cohen, M | 1 |
| Bremer, AM | 1 |
| Thomas, PR | 1 |
| Sinks, LF | 1 |
| Racca, AR | 1 |
| Wheeler, KT | 1 |
| Barker, M | 1 |
| Knebel, KD | 1 |
| Calogero, J | 1 |
| Rosenberg, A | 1 |
| Watne, K | 3 |
| Hannisdal, E | 2 |
| Nome, O | 3 |
| Hager, B | 3 |
| Hirschberg, H | 3 |
| Bradac, GB | 1 |
| Soffietti, R | 1 |
| Riva, A | 1 |
| Stura, G | 1 |
| Sales, S | 1 |
| Schiffer, D | 1 |
| Wester, K | 1 |
| Heier, M | 1 |
| Bobo, H | 1 |
| Rotman, M | 1 |
| Asbell, SO | 1 |
| Munari, L | 1 |
| Solero, CL | 1 |
| Botturi, M | 1 |
| Ogilvy-Stuart, AL | 1 |
| Shalet, SM | 1 |
| Gattamaneni, HR | 1 |
| August, C | 1 |
| Packer, R | 1 |
| Zimmerman, R | 1 |
| Sutton, L | 1 |
| Freid, A | 1 |
| Rorke, L | 1 |
| Bayever, E | 1 |
| Kamani, N | 1 |
| Kramer, E | 1 |
| Hasleton, PS | 1 |
| O'Driscoll, BR | 1 |
| Lynch, P | 1 |
| Webster, A | 1 |
| Kalra, SJ | 1 |
| Gattamaneini, HR | 1 |
| Woodcock, AA | 1 |
| Poulter, LW | 1 |
| Recht, L | 1 |
| Fram, RJ | 1 |
| Strauss, G | 1 |
| Fitzgerald, TJ | 1 |
| Liepman, M | 1 |
| Lew, R | 1 |
| Kadish, S | 1 |
| Sherman, D | 1 |
| Wilson, J | 1 |
| Greenberger, J | 1 |
| Ali-Osman, F | 1 |
| Stein, DE | 1 |
| Renwick, A | 1 |
| Bradford, R | 1 |
| Tonn, JC | 1 |
| Schönmayr, R | 1 |
| Kraemer, HP | 1 |
| Unsgaard, G | 1 |
| Helseth, E | 1 |
| Vik, R | 1 |
| Dalen, A | 1 |
| Deutsch, M | 1 |
| Green, SB | 1 |
| Strike, TA | 1 |
| Burger, PC | 3 |
| Robertson, JT | 1 |
| Selker, RG | 1 |
| Mealey, J | 1 |
| Ransohoff, J | 1 |
| Rodriguez, L | 1 |
| Chamberlain, M | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Zamorano, L | 1 |
| Katanick, D | 1 |
| Dujovny, M | 1 |
| Yakar, D | 1 |
| Malik, G | 1 |
| Ausman, JI | 1 |
| Arnold, DL | 2 |
| Shoubridge, EA | 2 |
| Emrich, J | 1 |
| Feindel, W | 2 |
| Villemure, JG | 2 |
| Mughal, TI | 1 |
| Glode, LM | 1 |
| Braun, TJ | 1 |
| Klingensmith, W | 1 |
| Geier, JM | 1 |
| Kindt, GW | 1 |
| Comella, G | 1 |
| Scoppa, G | 1 |
| De Marco, M | 1 |
| Ianniello, GP | 1 |
| Melillo, G | 1 |
| Coucourde, F | 1 |
| Zarrilli, D | 1 |
| Vance, RB | 1 |
| Salcman, M | 1 |
| Gebarski, S | 1 |
| Meyer, M | 1 |
| Chaffee, B | 1 |
| Bender, JF | 1 |
| Grillo-Lopez, AJ | 1 |
| Phillips, GL | 2 |
| Wolff, SN | 3 |
| Fay, JW | 1 |
| Herzig, RH | 1 |
| Lazarus, HM | 1 |
| Schold, C | 1 |
| Herzig, GP | 2 |
| Schold, SC | 1 |
| Vick, NA | 1 |
| DeLong, ER | 1 |
| Albright, RE | 1 |
| Bullard, DE | 1 |
| Khandekar, JD | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Strayer, DR | 1 |
| Weisband, J | 1 |
| Carter, WA | 1 |
| Black, P | 1 |
| Nidzgorski, F | 1 |
| Cook, AW | 1 |
| Bamberg, M | 1 |
| Budach, V | 1 |
| Stuschke, M | 1 |
| Gerhard, L | 1 |
| Barranco, SC | 1 |
| Townsend, CM | 1 |
| Jenkins, VK | 1 |
| Koester, SK | 1 |
| Ho, BY | 1 |
| Reumont, KJ | 1 |
| LoRusso, PM | 1 |
| Tapazoglou, E | 1 |
| Zarbo, RJ | 1 |
| Cullis, PA | 1 |
| Austin, D | 1 |
| Al-Sarraf, M | 1 |
| Johnson, DW | 1 |
| Parkinson, D | 1 |
| Wolpert, SM | 1 |
| Kasdon, DL | 1 |
| Kwan, ES | 1 |
| Laucella, M | 1 |
| Anderson, ML | 1 |
| Röttinger, EM | 1 |
| Smith, BD | 1 |
| Weidenmaier, W | 1 |
| Davis, DR | 1 |
| Griffin, TW | 1 |
| Pajak, TF | 1 |
| Fewer, D | 1 |
| Powell, MR | 1 |
| Jacobi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Randomized Study (Phase I Closed) of Radiation Therapy and Temozolomide Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma And Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)[NCT00004259] | Phase 3 | 230 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| Phase II Trial of Pre-Irradiation Chemotherapy With BCNU, Cisplatin and Oral Etoposide Combined With Radiation Therapy in the Treatment of Grade 3 Astrocytoma (Anaplastic Astrocytoma)[NCT00003621] | Phase 2 | 29 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| A Phase II Study of SarCNU (NSC 364432) in Patients With Malignant Glioma[NCT00036660] | Phase 2 | 10 participants (Actual) | Interventional | 2002-01-10 | Completed | ||
| EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY[NCT00002620] | Phase 3 | 212 participants (Anticipated) | Interventional | 1994-11-30 | Completed | ||
| Phase I Trial of AZD8055, An Oral MTOR Kinase Inhibitor, for Adults With Recurrent Gliomas[NCT01316809] | Phase 1 | 22 participants (Actual) | Interventional | 2011-03-04 | Completed | ||
| (11C)N-Desmethyl-Loperamide as a Marker of P-Glycoprotein Function in Patients With Gliomas[NCT01281982] | 2 participants (Actual) | Observational | 2011-01-13 | Terminated | |||
| Phase I Trial of AZD7451, A Topomysin-Receptor Kinase (TRK) Inhibitor, For Adults With Recurrent Glioblastoma Multiforme (GBM)[NCT01468324] | Phase 1 | 14 participants (Actual) | Interventional | 2011-10-05 | Completed | ||
| A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII[NCT01454596] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2012-05-16 | Completed | ||
| Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?[NCT00846859] | Phase 2 | 162 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 3.9 |
| RT + BCNU/CCNU | 3.8 |
Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Progression-free survival time is defined as time from randomization to date of progression or death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 4.0 |
| Unmthylated MGMT | 2.1 |
Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. Tumor tissue samples were analyzed for methylation status of methyl guanine methyl transferase (MGMT), classified as methylated vs. unmethylated. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | years (Median) |
|---|---|
| Methylated MGMT | 7.2 |
| Unmthylated MGMT | 3.1 |
Three-year rate is reported. Progression is defined as a radiographic increase in size of the lesion by > 25%, recurrence of the study lesion, or the development of new lesions, confirmed by imaging. Time to tumor progression was estimated using the cumulative incidence function (CIF) on tumor progression, with death as a competing risk. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | months (Median) |
|---|---|
| Radiation Therapy + Temozolomide (TMZ) | 45.4 |
| RT + BCNU/CCNU | 54.7 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the adverse event (AE). The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. Dose limiting toxicity (DLT) was defined as grade 3+ pulmonary toxicity, grade 4+ thrombocytopenia (< 25,000 for 5 days), neutropenia (< 500/microl for 7 days), or neutropenia of any duration with fever requiring hospital admission after one dose reduction of 50% in BCNU. A 20% rate of grade 3+ pulmonary toxicities or a 40% rate of grade 4+ thrombocytopenia and neutropenia was considered unacceptable for a treatment arm combining RT, TMZ, and BCNU. (NCT00004259)
Timeframe: From start of treatment to 3 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Subjects with Pulmonary DLT | Subjects with Hematologic DLT | |
| Pilot Arm #1: RT+TMZ+BCNU | 1 | 4 |
| Pilot Arm #2: RT+TMZ+BCNU | 0 | 3 |
Adverse events were graded using CTCAE v2.0. Grade refers to the severity of the AE. The CTCAE v2.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The number of patients with grade or higher toxicity was calculated overall and for non-hematologic toxicity only. Per the protocol, the pilot arms were not included in the Phase III analyses. (NCT00004259)
Timeframe: From randomization to date of death. Patients are followed until death. Analysis occurs after 155 deaths have been reported, estimated at 5.5 years from the study opening.
| Intervention | participants (Number) | |
|---|---|---|
| Overall toxicity | Non-hematologic toxicity | |
| Radiation Therapy + Temozolomide (TMZ) | 46 | 31 |
| RT + BCNU/CCNU | 75 | 34 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
CAR and vector presence were quantitated in peripheral blood mononuclear cell (PBMC) samples using established polymerase chain reaction (PCR) techniques (NCT01454596)
Timeframe: 1 month post transplant
| Intervention | K/µL (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 23 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 70 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 36 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 67 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 7 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 43 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 28 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 25 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 12 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 67.5 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | NA |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 8 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01454596)
Timeframe: 51 dys Grp A, Cohort 1; Cohort 2:68 dys; Cohort 3:40 dys; Grp B, Cohort 1:67 dys; Cohort 2:48 dys; Cohort 3:55 dys; Cohort 4: 46 dys; Cohort 5:147 dys; C. Ster/No Ster Grp, Cohort 6:12 mos, 26 dys; Cohort 7:11 mos, 18 dys; Cohort 8:7 dys; Cohort 9:70 dys.
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 1 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 3 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 3 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Objective response was assessed by comparison with baseline dynamic contrast enhanced magnetic resonance imaging with perfusion using Neuro-oncology Working Group proposed guidelines. Complete Response is disappearance of all measurable and non-measurable disease for at least 4 weeks. Partial Response is >/= 50% decrease in lesions for at least 4 weeks. Stable Disease does not meet the criteria for complete response, partial response or progression and requires stable lesions compared with baseline. Progression is >/= 25% increase in lesions. (NCT01454596)
Timeframe: 4 weeks after cell infusion and monthly as feasible up to 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 0 |
Aggregate of all adverse events ≥Grade 3 that are possibly, probably, and definitely related to treatment. Adverse events were assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). Per CTCAE, Grade 3 adverse events are severe, Grade 4 is life threatening, and Grade 5 is death. (NCT01454596)
Timeframe: From 4 weeks after cell infusion up to 77 days
| Intervention | adverse events (Number) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 0 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 0 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 0 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 0 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 0 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 0 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 1 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 1 |
Progression was assessed by the Response Assessment in Neuro-Oncology (RANO) criteria and is defined as the circumstance when the magnetic resonance imaging (MRI) scan is ranked -2 (definitely worse) or -3 (development of a new lesion). (NCT01454596)
Timeframe: Time from the date of registration to the date of first observation of progressive disease up to 6 months after end of treatment
| Intervention | months (Median) |
|---|---|
| Group A (Steroids) - Cohort 1: 1x10(7) | 1.1 |
| Group A (Steroids) - Cohort 2: 3x10(7) | 1.1 |
| Group A (Steroids) - Cohort 3: 1x10(8) | 1.3 |
| Group B (No Steroids) - Cohort 1: 1x10(7) | 1.9 |
| Group B (No Steroids) - Cohort 2: 3x10(7) | 2.0 |
| Group B (No Steroids) - Cohort 3: 1x10(8) | 1.5 |
| Group B (No Steroids) - Cohort 4: 3x10(8) | 1.2 |
| Group B (No Steroids) - Cohort 5: 1x10(9) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 6: 3x10(9) | 2.7 |
| Combined Steroids/no Steroids) - Cohort 7: 1x10(10) | 1.1 |
| Combined Steroids/no Steroids) - Cohort 8: 3-6x10(10) | 0 |
| Combined Steroids/no Steroids) - Cohort 9: 3x10(10) | 2.0 |
12 reviews available for carmustine and Astrocytoma
| Article | Year |
|---|---|
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Glioblastoma multiforme: pathology, natural history and treatment.
Topics: Adolescent; Adult; Aged; Antigens, Neoplasm; Antigens, Surface; Astrocytoma; Brain Neoplasms; Carmus | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
[Chemoradiation for malignant brain tumors].
Topics: Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
[Chemoradiation for malignant brain tumors].
Topics: Antineoplastic Agents; Astrocytoma; Bleomycin; Brain Neoplasms; Carmustine; Chemotherapy, Adjuvant; | 1997 |
Bone marrow metastasis in astrocytic gliomata.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Neoplasms; Brai | 1998 |
Bone marrow metastasis in astrocytic gliomata.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Neoplasms; Brai | 1998 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
[Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; C | 2001 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Combined modality therapy for intracranial tumors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Cranioph | 1975 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment.
Topics: Aged; Astrocytoma; Brain; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Male; Middle Ag | 1986 |
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature.
Topics: Adult; Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glial Fibrillary Acidic Prote | 1988 |
Intracranial astrocytoma with diffuse bone marrow metastasis: a case report and review of the literature.
Topics: Adult; Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glial Fibrillary Acidic Prote | 1988 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
[Chemotherapy of brain neoplasms in children].
Topics: Age Factors; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; Carmustine; Child; Cyclophosphamide; | 1974 |
33 trials available for carmustine and Astrocytoma
| Article | Year |
|---|---|
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2016 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
[Chemotherapy of recurrent supratentorial malignant gliomas (phase II study)].
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Dacarbazin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 2004 |
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brai | 2005 |
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; | 2005 |
A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; | 2005 |
Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Astrocytoma; Canada; Carbon Monoxide; | 2005 |
Phase II trial of SarCNU in malignant glioma: unexpected pulmonary toxicity with a novel nitrosourea: a phase II trial of the national cancer institute of canada clinical trials group.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Astrocytoma; Canada; Carbon Monoxide; | 2005 |
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Chemotherapy, | 2008 |
Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Chemotherapy, | 2008 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
Topics: Adult; Age Factors; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials | 1983 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Perioperative carmustine chemotherapy for malignant brain tumors.
Topics: Adolescent; Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Combine | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Accelerated hyperfractionated radiation therapy for malignant glioma. A phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1995 |
Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; | 1993 |
Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Female; Glioblastoma; Humans; Male; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Computer Simulation; Glioblastoma; | 1995 |
Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02.
Topics: Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Computer Simulation; Glioblastoma; | 1995 |
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Carmustine; Chemother | 1996 |
Intravenous administration of high doses of carboplatin in multimodal treatment of high grade gliomas: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carboplatin; Carmustine; Chemother | 1996 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 1997 |
Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 1997 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Cohort Studies | 2001 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Diseases; Carm | 2002 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
Treatment of brain tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Cell Divis | 1977 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
Combined intra-arterial chemotherapy followed by radiation in astrocytomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 1992 |
Combined intra-arterial chemotherapy followed by radiation in astrocytomas.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astro | 1992 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Combined intra-arterial chemotherapy and irradiation of malignant gliomas.
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Eye Diseases | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
Cisplatin and etoposide combination therapy for primary glial tumors: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1991 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transplantation | 1990 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Glioblastoma; Glioma; H | 1989 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
Topics: Astrocytoma; Brain Neoplasms; Carcinosarcoma; Carmustine; Cerebral Angiography; Ependymoma; Evaluati | 1972 |
95 other studies available for carmustine and Astrocytoma
| Article | Year |
|---|---|
p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.
Topics: Astrocytoma; Carmustine; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Prognos | 2018 |
p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.
Topics: Astrocytoma; Carmustine; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Prognos | 2018 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
Independent association of extent of resection with survival in patients with malignant brain astrocytoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmust | 2009 |
Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biocompatible Materials; Carmustine; Da | 2010 |
Carmustine wafers (Gliadel) plus concomitant temozolomide therapy after resection of malignant astrocytoma: growing evidence for safety and efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biocompatible Materials; Carmustine; Da | 2010 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Favorable prognosis in patients with high-grade glioma with radiation necrosis: the University of Colorado reoperation series.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Colorado; | 2011 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral V | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combin | 2012 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat O
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Fema | 2011 |
Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without previous gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas: in regard to Noel et al. (Int J Radiat O
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemoradiotherapy; Fema | 2011 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Comment on Bock et al. Occlusion of surgical opening of the ventricular system with fibrinogen-coated collagen fleece: a case collection study. Acta Neurochir (2011) 153:533-539.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Cerebral Ventricle Neop | 2012 |
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combi | 2013 |
Prolonged survival associated with the use of intraoperative carmustine (Gliadel) in a paediatric patient with recurrent grade III astrocytoma.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combi | 2013 |
Goosebumps.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Dexamethasone; Diagnosis, Differential; Frontal Lobe; Huma | 2002 |
Goosebumps.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Dexamethasone; Diagnosis, Differential; Frontal Lobe; Huma | 2002 |
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
BCNU-DBD (Dibromodulcitol) chemotherapy of recurrent supratentorial anaplastic astrocytomas and glioblastomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astr | 2002 |
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modali | 2003 |
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modali | 2003 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
Combination chemotherapy with carmustine and cisplatin followed by procarbazine, lomustine, and vincristine for adult high-grade astrocytoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 2005 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
Topics: Antineoplastic Agents; Astrocytoma; Blotting, Western; Carmustine; Cell Cycle; Cisplatin; Cyclin-Dep | 2005 |
Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin.
Topics: Antineoplastic Agents; Astrocytoma; Blotting, Western; Carmustine; Cell Cycle; Cisplatin; Cyclin-Dep | 2005 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
Response to chemotherapy of a radiation-induced glioblastoma multiforme.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Child, Preschool | 2006 |
Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Edema; Brain Neoplasms; Carmustine; Com | 2006 |
Patient with resected anaplastic astrocytoma and an image suggestive of relapse.
Topics: Adult; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Edema; Brain Neoplasms; Carmustine; Com | 2006 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Imaging response in malignant glioma, RTOG 90-06.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Disease Progres | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Fatal outcome related to carmustine implants in glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Chemothera | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cel | 2007 |
Valproic acid increases the in vitro effects of nitrosureas on human glioma cell lines.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Astrocytoma; Carmustine; Cel | 2007 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 2008 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Variable response to 1,3-bis(2-chloroethyl)-1-nitrosourea of human glioma cells sorted according to DNA content.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cells, Cultured; Child; Combined Modality The | 1984 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
Treatment of malignant gliomas in adults with BCNU plus metronidazole.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Female; Gliobl | 1984 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Age-related chemosensitivity of stem cells from human malignant brain tumours.
Topics: Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; DNA Repair; Glioblastoma | 1982 |
Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine).
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Central Nervous System Diseases; | 1981 |
Ophthalmic and central nervous system complications following intracarotid BCNU (Carmustine).
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Central Nervous System Diseases; | 1981 |
Visual-evoked responses. A new abnormality with focal retinal damage.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Evoked Potentials, Visual; Female; Humans; Middle Aged; Pa | 1981 |
Visual-evoked responses. A new abnormality with focal retinal damage.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Evoked Potentials, Visual; Female; Humans; Middle Aged; Pa | 1981 |
Long-term survivors of high-grade malignant astrocytomas.
Topics: Adult; Age Factors; Astrocytoma; Brain Neoplasms; Carmustine; Evaluation Studies as Topic; Glioblast | 1980 |
Long-term survivors of high-grade malignant astrocytomas.
Topics: Adult; Age Factors; Astrocytoma; Brain Neoplasms; Carmustine; Evaluation Studies as Topic; Glioblast | 1980 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: a follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1983 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
Treatment of recurrent brain tumors with intra-arterial cis-platinum and BCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Ar | 1984 |
The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 1983 |
The failure of human leukocyte interferon to influence the growth of human glioma cell populations: in vitro and in vivo studies.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; | 1983 |
Carmustine and Baker's antifol combination chemotherapy for primary brain tumors progressive after irradiation and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Count; Brain Neoplasm | 1984 |
Carmustine and Baker's antifol combination chemotherapy for primary brain tumors progressive after irradiation and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Blood Cell Count; Brain Neoplasm | 1984 |
BCNU solubility and toxicity in the treatment of malignant astrocytomas.
Topics: Astrocytoma; Carmustine; Chemical Phenomena; Chemistry; Ethanol; Humans; Solubility; Solutions; Wate | 1984 |
BCNU solubility and toxicity in the treatment of malignant astrocytomas.
Topics: Astrocytoma; Carmustine; Chemical Phenomena; Chemistry; Ethanol; Humans; Solubility; Solutions; Wate | 1984 |
Treatment of grade III and IV astrocytoma with high-dose irradiation: schedule and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1984 |
Treatment of grade III and IV astrocytoma with high-dose irradiation: schedule and chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustin | 1984 |
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Humans; Lung; Lung Diseases; Male; Pulmonary Fibros | 1984 |
BCNU (1,3-bis-(2-chloroethyl)-1-nitrosurea) lung. Drug-induced pulmonary changes.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Humans; Lung; Lung Diseases; Male; Pulmonary Fibros | 1984 |
BCNU treatment of astrocytomas: erratum.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Humans | 1984 |
BCNU treatment of astrocytomas: erratum.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Humans | 1984 |
Disseminated intravascular coagulation--a complication of 1,3-bis(2-chlorethyl)-nitrosourea therapy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Disseminated Intravascular Coagulation; Female; Hum | 1983 |
Disseminated intravascular coagulation--a complication of 1,3-bis(2-chlorethyl)-nitrosourea therapy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Disseminated Intravascular Coagulation; Female; Hum | 1983 |
Fatal pneumothorax in "BCNU lung".
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Humans; Parietal Lobe; Pneumo | 1982 |
Fatal pneumothorax in "BCNU lung".
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Humans; Parietal Lobe; Pneumo | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Failure of corticosteroids to prevent carmustine-induced pulmonary fibrosis in a woman with astrocytoma.
Topics: Adrenal Cortex Hormones; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Huma | 1981 |
Failure of corticosteroids to prevent carmustine-induced pulmonary fibrosis in a woman with astrocytoma.
Topics: Adrenal Cortex Hormones; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Frontal Lobe; Huma | 1981 |
Rapidly progressive, fatal pulmonary fibrosis induced by carmustine.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Female; Humans; Lung; Middle Aged; Postoperative Care; Pul | 1980 |
Rapidly progressive, fatal pulmonary fibrosis induced by carmustine.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Female; Humans; Lung; Middle Aged; Postoperative Care; Pul | 1980 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 41-1980.
Topics: Astrocytoma; Carmustine; Cerebellar Neoplasms; Child, Preschool; Diagnosis, Differential; Female; Hu | 1980 |
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 41-1980.
Topics: Astrocytoma; Carmustine; Cerebellar Neoplasms; Child, Preschool; Diagnosis, Differential; Female; Hu | 1980 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergis | 1995 |
In vivo enhanced antitumor activity of carmustine [N,N'-bis(2-chloroethyl)-N-nitrosourea] by simvastatin.
Topics: Animals; Astrocytoma; Carmustine; Cell Cycle; Cell Division; Cell Line; DNA, Neoplasm; Drug Synergis | 1995 |
Chromosome number and carmustine sensitivity in human gliomas.
Topics: Adolescent; Adult; Aged; Aneuploidy; Astrocytoma; Brain Neoplasms; Carmustine; Child; Chromosome Abe | 1993 |
Chromosome number and carmustine sensitivity in human gliomas.
Topics: Adolescent; Adult; Aged; Aneuploidy; Astrocytoma; Brain Neoplasms; Carmustine; Child; Chromosome Abe | 1993 |
BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clone Cells; Diploidy; Drug Resistance; Drug Screening Ass | 1993 |
BCNU-sensitivity in parental cells and clones from four freshly resected near-diploid human gliomas: an astrocytoma, an anaplastic astrocytoma and two glioblastomas multiforme.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clone Cells; Diploidy; Drug Resistance; Drug Screening Ass | 1993 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Glio | 1996 |
Inter- and intracellular heterogeneity of O6-alkylguanine-DNA alkyltransferase expression in human brain tumors: possible significance in nitrosourea therapy.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Glio | 1996 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasm | 1997 |
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carm | 1999 |
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carm | 1999 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Effects of radiation on a model of malignant glioma invasion.
Topics: Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modality Therapy; Dose-Response | 1999 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |
Evaluation of early response to SU101 target-based therapy in patients with recurrent supratentorial malignant gliomas using FDG PET and Gd-DTPA MRI.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biologica | 2000 |
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Astrocytoma; ATP-Binding Cassette Transporte | 2000 |
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Astrocytoma; ATP-Binding Cassette Transporte | 2000 |
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemo | 2000 |
Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain | 2002 |
Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Biopsy; Brain | 2002 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Single-agent chemotherapy of brain tumors. A five-year review.
Topics: Astrocytoma; Bone Marrow Diseases; Brain Neoplasms; Carmustine; Glioma; Humans; Imidazoles; Lomustin | 1976 |
Chemotherapeutic trials on human malignant astrocytomas in organ culture.
Topics: Antineoplastic Agents; Astrocytoma; Carmustine; Cell Survival; Cyanides; Drug Evaluation, Preclinica | 1977 |
Chemotherapeutic trials on human malignant astrocytomas in organ culture.
Topics: Antineoplastic Agents; Astrocytoma; Carmustine; Cell Survival; Cyanides; Drug Evaluation, Preclinica | 1977 |
Immunobiology of primary intracranial tumors.
Topics: Alpharetrovirus; Animals; Astrocytoma; BCG Vaccine; Brain Neoplasms; Carmustine; Disease Models, Ani | 1977 |
Immunobiology of primary intracranial tumors.
Topics: Alpharetrovirus; Animals; Astrocytoma; BCG Vaccine; Brain Neoplasms; Carmustine; Disease Models, Ani | 1977 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
[Treatment of intracranial tumors with Nitrumon (Litrumon; BCNU; 1,3-bis (2-chlorethyl)-1-nitrosourea)].
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Child; Female; Humans; Male; Middle Age | 1979 |
[Treatment of intracranial tumors with Nitrumon (Litrumon; BCNU; 1,3-bis (2-chlorethyl)-1-nitrosourea)].
Topics: Adolescent; Adult; Astrocytoma; Brain Neoplasms; Carmustine; Child; Female; Humans; Male; Middle Age | 1979 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethas | 1978 |
Chemotherapy in recurrent noncystic low-grade astrocytomas of the cerebrum in children.
Topics: Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethas | 1978 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Dose-Response Relatio | 1975 |
In vitro evaluation of in vivo brain tumor chemotherapy with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Cell Survival; Clone Cells; Dose-Response Relatio | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Long-term survival of patients treated with BCNU for brain tumors.
Topics: Adolescent; Adult; Astrocytoma; Bone Marrow; Brain; Brain Neoplasms; Carmustine; Dose-Response Relat | 1975 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
Selective intra-arterial chemotherapy with BCNU in recurrent malignant gliomas.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Female; Glioblastoma; Humans; Infusions, Intra-Arte | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Effect of intra-arterial cisplatin and 1,3-bis(2chloroethyl)-1-nitrosourea (BCNU) dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intra-arterial dosage calculation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Cis | 1992 |
Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.
Topics: Adult; Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Front | 1992 |
Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials.
Topics: Adult; Age Factors; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Front | 1992 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Thyroid function after treatment of brain tumors in children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine | 1991 |
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
Topics: Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Ependymoma; Humans; Lung; Medulloblastoma; Microsc | 1991 |
Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma.
Topics: Astrocytoma; Biopsy; Brain Neoplasms; Carmustine; Ependymoma; Humans; Lung; Medulloblastoma; Microsc | 1991 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Preirradiation chemotherapy of supratentorial malignant primary brain tumors with intracarotid cis-platinum (CDDP) and i.v. BCNU. A phase II trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplas | 1990 |
Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Cisplatin; DNA, Neoplasm; Drug Resistan | 1990 |
Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines.
Topics: Astrocytoma; Blotting, Western; Brain Neoplasms; Carmustine; Cisplatin; DNA, Neoplasm; Drug Resistan | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
Sensitivity of human malignant intracranial tumors against MCNU in vitro in comparison to ACNU and BCNU.
Topics: Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carmustine; Drug Screening Assays, Antitu | 1990 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea and alpha-difluoromethylornithine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Tumour recurrence vs radionecrosis: an indication for multitrajectory serial stereotactic biopsies.
Topics: Astrocytoma; Biopsy, Needle; Brain; Brain Neoplasms; Carmustine; Combined Modality Therapy; Female; | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Early metabolic changes following chemotherapy of human gliomas in vivo demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Glioma; Humans; Hydrogen-Ion Concentration; Infusions, Int | 1989 |
Phase I clinical trial of intracarotid bis-chloroethylnitrosourea (BCNU) and 2' dioxy-5-fluorouridine (FUDR) in malignant astrocytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Caro | 1986 |
Phase I clinical trial of intracarotid bis-chloroethylnitrosourea (BCNU) and 2' dioxy-5-fluorouridine (FUDR) in malignant astrocytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Caro | 1986 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Radiotherapy and combination chemotherapy with carmustine, vincristine, and procarbazine (BVP) in primary brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Combined M | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Supraophthalmic carotid infusion for recurrent glioma: rationale, technique, and preliminary results for cisplatin and BCNU.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Car | 1985 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Aziridines; Azirines; Benzoquinones; Bone Marrow; B | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
Topics: Adolescent; Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Chil | 1986 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
High-dose carmustine with autologous bone marrow transplantation for the adjuvant treatment of high-grade gliomas of the central nervous system.
Topics: Adult; Aged; Astrocytoma; Bone Marrow Transplantation; Brain Diseases; Brain Neoplasms; Carmustine; | 1987 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Be | 1987 |
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Aziridines; Be | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cell Line; Colony-Forming Units Assay; Dose-Response Relat | 1987 |
Growth of astrocytomas in the human tumor clonogenic assay and sensitivity to mismatched dsRNA and interferons.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cell Line; Colony-Forming Units Assay; Dose-Response Relat | 1987 |
Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas.
Topics: Animals; Astrocytoma; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Lethal D | 1988 |
Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas.
Topics: Animals; Astrocytoma; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Lethal D | 1988 |
Changes in drug sensitivity of a human astrocytoma clone previously treated with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea in vitro.
Topics: Astrocytoma; Carmustine; Cell Survival; Clone Cells; Doxorubicin; Drug Resistance; Galactitol; Human | 1988 |
Changes in drug sensitivity of a human astrocytoma clone previously treated with 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea in vitro.
Topics: Astrocytoma; Carmustine; Cell Survival; Clone Cells; Doxorubicin; Drug Resistance; Galactitol; Human | 1988 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Intracarotid chemotherapy with 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) in 5% dextrose in water in the treatment of malignant glioma.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; | 1987 |
Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Energy Metabolism; Femal | 1987 |
Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Energy Metabolism; Femal | 1987 |
High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemical a | 1986 |
High-dose carmustine and high-dose etoposide: a treatment regimen resulting in enhanced hepatic toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carmustine; Chemical a | 1986 |
Intracarotid BCNU leukoencephalopathy.
Topics: Astrocytoma; Autopsy; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Humans; Infusion | 1986 |
Intracarotid BCNU leukoencephalopathy.
Topics: Astrocytoma; Autopsy; Brain; Brain Neoplasms; Carmustine; Carotid Artery, Internal; Humans; Infusion | 1986 |
pH-induced modification of BCNU toxicity on glial cells.
Topics: Astrocytoma; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; H | 1986 |
pH-induced modification of BCNU toxicity on glial cells.
Topics: Astrocytoma; Carmustine; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Humans; H | 1986 |
Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Follow-Up Studies; Huma | 1985 |
Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.
Topics: Adolescent; Adult; Aged; Astrocytoma; Carmustine; Combined Modality Therapy; Follow-Up Studies; Huma | 1985 |